Comment on “Opioid-based versus opioid-sparing patient-controlled analgesia using ketorolac and nefopam after total knee arthroplasty: a randomized, double-blind, non-inferiority trial”
Article information
Dear Editor,
I read with great interest the article by Han et al. [1], which evaluated the efficacy of opioid-sparing patient-controlled analgesia (PCA) using ketorolac and nefopam after total knee arthroplasty (TKA). I commend the authors for conducting this randomized, double-blind, non-inferiority trial that addresses the critical need for opioid stewardship in orthopedic surgery. However, I respectfully wish to highlight several methodological and interpretive considerations that may further strengthen the clinical applicability of these findings.
First, regarding statistical analysis and blinding, the conclusion of non-inferiority appears to be based solely on a per-protocol analysis. According to the CONSORT guidelines for non-inferiority trials, both intention-to-treat and per-protocol analyses should be reported to assess the robustness of findings, as exclusions may bias the results toward non-inferiority [2]. Furthermore, the authors noted that the investigator preparing the PCA was not blinded. Although the data collectors were blinded, the lack of blinding among the personnel involved in intervention preparation may have introduced performance bias, which future studies should aim to avoid.
Second, the reliance of the study on Visual Analog Scale pain scores and categorical mobility scores may not fully capture patient-centered recovery. Contemporary perioperative trials increasingly emphasize more holistic measures, such as the Quality of Recovery-15, which assesses emotional well-being and physical independence [3]. In addition, objective functional metrics that are highly relevant to TKA recovery, such as range of motion and the Timed Up and Go test, were not included. Relying solely on a simple ambulation score may overlook the subtle but clinically meaningful benefits of the opioid-sparing regimen for early joint function and rehabilitation [4].
Finally, caution is warranted when interpreting the safety findings derived from a sample of only 98 patients. This sample size was likely insufficient to detect rare but clinically important adverse events associated with non-steroidal anti-inflammatory drugs, such as acute kidney injury or gastrointestinal bleeding, as well as nefopam-related hemodynamic effects such as tachycardia, which were not explicitly monitored [5]. Although the reduction in postoperative nausea and vomiting is encouraging, larger multicenter trials are needed to establish the safety profiles of ketorolac- and nefopam-based infusions, particularly in older patients with multiple comorbidities.
In summary, this study provides valuable evidence supporting an opioid-sparing PCA strategy after TKA. However, additional analyses, broader recovery-oriented outcome measures, and more comprehensive safety evaluations would further strengthen the interpretation and generalizability of these promising findings.
Notes
Funding: None.
Conflicts of Interest: No potential conflict of interest relevant to this article was reported.
